The concern over global epidemics of diabetes and obesity has risen. Obesity is a conspicuous risk factor for the development of type 2 diabetes, and with the global obesity rates rising, diabetes can be considered as a global public health problem. The aging of society, lifestyle changes and epigenetic modifications have all caused a rapid increase in diabetes prevalence, especially in Asian countries. One explanation for the large impact of lifestyle changes on diabetes prevalence is the change in dietary habits. Diets containing high amounts of fat can easily provoke insulin resistance in obesity-prone Asian individuals. When adaptive b-cell proliferation and b-cell mass expansion are insufficient to produce sufficient insulin to overcome diet-induced insulin resistance, type 2 diabetes is manifested. A progressive decline in the insulin-producing b-cell volume is an important feature of the type 2 diabetes pathophysiology, prompting further investigation of the mechanisms underlying the regulation of the b-cell mass. Some studies have already shown that adaptive b-cell replication is observed after short-term high-fat diet (HFD) feeding, before insulin resistance and obesity develop. This represents the reasonable physiological response against diabetes onset. A human autopsy study has suggested that obese individuals without diabetes have higher b-cell masses as compared with lean non-diabetic individuals or obese individuals with diabetes. Thus, mice with HFDinduced obesity might serve as a useful physiological model of b-cell proliferation and mass expansion to study the pathophysiology of human type 2 diabetes.
Glucokinase (Gck) acts as a glucose sensor in pancreatic b-cells, and plays a central role in glucose-stimulated insulin secretion. b-cell-specific Gck-heterozygous-knockout mice showed decreased b-cell replication after HFD feeding, resulting in insufficient adaptative increment of the b-cell mass In a recent report, Lakshmipathi et al. . Lakshmipathi et al. 3 showed that overexpression of KD-PKCf blunted glucose-induced cyclin D2 expression in INS-1 cells and mouse islets. Cyclin D2 overexpression rescued the inhibition of glucosemediated b-cell proliferation induced by KD-PKCf. This suggests that cyclin D2 is downstream of PKCf in the glucoseelicited b-cell replication. KD-PKCf also attenuated glucose-induced phosphorylation of the mechanistic targets of rapamycin (mTOR), ribosomal protein S6 kinase beta-1 (p70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1). Inhibition of mTOR with rapamycin reduced glucose-induced cyclin D2 expression in the INS-1 cells. KD-PKCf had no effect on phosphorylation of Akt or glycogen synthase kinase3b (GSK-3b). Based on these results, they concluded that PKCf regulates cyclin D2 expression through mTOR activation, independent of Akt, in the b-cells 3 . However, it is possible that phosphorylation of PKCf is downstream of Akt and/or GSK-3b, and that the alteration of protein synthesis, mitochondrial functions or autophagy by rapamycin could influence the activity of PKCf. Glucose-and HFDinduced b-cell proliferation is mediated by insulin receptor substrate-2 (IRS-2) 1, 4 . Glucose-induced IRS-2 upregulation is thought to be mediated through the cyclic adenosine monophosphate response element binding protein or calcium/ calmodulin-dependent phosphatase calcineurin/nuclear factor of activated Tcells signaling 1, 5 . This glucose-IRS2 pathway is also reportedly mediated through mTOR and cyclin D2 4 . Taken together, glucose and HFD feeding stimulates IRS-2/PI3K signaling through calcineurin or cyclic adenosine monophosphate response element binding protein, followed by activation of PKCf and mTOR-mediated cyclin D2 expression in the b-cells (Figure 1) .
As glucokinase-mediated glucose signaling is required for adaptive b-cell proliferation under the condition of HFDinduced obesity 1 , glucose is a prominent mitogenic component for the b-cells.
Insulin treatment also induces phosphorylation of PKCf, which promotes mTOR activation and b-cell proliferation 3 . However, the contribution of insulin in the adaptive b-cell proliferation under the condition of HFD-induced obesity is still controversial. b-Cell-specific insulin receptor-knockout mice failed to show adaptive b-cell hyperplasia in response to HFD feeding and showed nuclear localization of the forkhead box O1, with reduction in the pancreatic and . The role of insulin/ insulin receptor signaling on the ability of b-cells to replicate in response to insulin resistance remains controversial. Activation of protein kinase Cf (PKCf) requires phosphoinositide 3-kinase (PI3K) activity; however, the precise mechanism remains unclear. Mechanistic targets of rapamycin complex 1 (mTORC1) activity has also been associated with adenosine monophosphate-activated protein kinase (AMPK), Akt, glycogen synthase kinase-3b (GSK-3b) and feedback signaling of p70S6K. The potential role of PKCf in the induction of the mTORC1 pathway and cyclin D2 expression requires further investigation. 4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; CREB, cyclic adenosine monophosphate response element binding protein; ERK, extracellular signal-regulated kinases; NFAT, nuclear factor of activated T-cells; p70S6K, ribosomal protein S6 kinase beta-1; Tsc2/Tsc1, tuberous sclerosis complex 2/1.
duodenal expressions of homeobox-1 6 . This phenotype is similar to that of bcell-specific Gck-heterozygous-knockout mice reared on a HFD, which showed an increased percentage of nuclear forkhead box O1-positive b-cells 1 . Furthermore, overexpression of IRS-2 induced forkhead box O1 nuclear export in HFD-fed Gckheterozygous-knockout mice 1 . However, according to the report from Stamateris et al. 4 , insulin receptor stimulation is not sufficient for b-cell replication. They showed that both glucose and insulin induced phosphorylation of p70S6K, 4EBP and Akt as an acute response, at 2-15 min. However, after chronic stimulation for 72 h, glucose stimulated p70S6K and 4EBP1, but not Akt, suggesting that mTOR was activated by glucose stimulation. On the contrary, insulin upregulated Akt, but could not induce p70S6K and 4EBP1 phosphorylation. Stamateris et al. 4 also showed that insulin receptor and extracellular signal-regulated kinases were not necessary for glucoseinduced b-cell proliferation, by using inhibitors or short hairpin ribonucleic acid (shRNA) knockdown. It might be interesting to examine PKCf expression and phosphorylation in the b-cells of HFD-fed b-cell-specific insulin receptorknockout or Gck-heterozygous-knockout mice. High concentrations of insulin can cross-react with insulin-like growth factor-1 receptor expressed on b-cells. Because there is a functional redundancy between the signals transduced by the insulin-like growth factor-1 receptor and insulin receptor, the insulin-like growth factor-1 receptor-mediated pathway might be involved in PKCf-mediated bcell replication under the HFD-induced hyperinsulinemic state. Further studies are required to confirm the role of insulin and PKCf in adaptive b-cell replication induced by HFD.
PKCf might be promising for inducing physiological adaptive b-cell replication and serve as a therapeutic target to design means for b-cell mass expansion in diabetes patients. However, we need to clarify whether PKCf can actually amplify the 'functional' b-cell mass under diabetic conditions. Both b-cellspecific KD-PKCf-transgenic mice and b-cell-specific PKCf-knockout mice showed normal glucose and insulin homeostasis after receiving a HFD for a week 3 . The contribution of PKCf to compensatory b-cell hyperplasia has not yet been precisely assessed. A study involving prolonged HFD feeding with apparent obesity and insulin resistance would be required to evaluate the significance of PKCf as a regulator of the adaptive response of b-cells. Furthermore, the involvement of PKCf in the adaptive b-cell mass expansion in response to other physiological demands, such as pregnancy or aging, is unclear. Although rat-insulin promoter-driven PKCf-transgenic mice showed b-cell proliferation and b-cell mass expansion 7 , the impact of PKCf on the regulation of the b-cell mass under the condition of diabetes (e.g., diabetes model mice) is unclear. Studies are warranted to explore whether PKCf has an effect on apoptosis, neogenesis or transdifferentiation of b-cells. Of considerable interest, the expression level of cyclin D2, a downstream molecule to PKCf, is extremely low in human b-cells. However, PKCftransgenic mice also showed increased expressions of cyclin D1, cyclin D3 and cyclin A in the islets 7 . Perhaps most importantly, study of the role of PKCf in human b-cells is indispensable for paving the way for more relevant clinical investigations.
